Navigation Links
Gentris Corporation Launches New Pharmacogenomics Services
Date:7/12/2012

MORRISVILLE, N.C., July 12, 2012 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository services, announced today that it has expanded its genomic biomarker services by incorporating multiple technology platforms into its 24,000 sq. ft., CLIA-certified, GLP-compliant laboratory. Gentris has integrated the Affymetrix GCS3000, Sequenom MassArray, and LifeTech Ion Torrent technologies in a continued effort to identify polymorphisms involved in drug response and adverse drug events as well as in determining somatic mutations in cancer.  

Gentris has utilized Affymetrix DMET™ Plus analysis in a number of clinical studies, including oncology clinical trials. DMET™ Plus analysis allows drug developers to understand how variations in drug metabolism enzymes and drug transporters between patients affects adverse drug responses and treatment efficacy. This type of analysis has been implemented by major pharmaceutical companies in Phase I through Phase III clinical trials focused on numerous therapeutic areas.  Most recently, Gentris collaborated with Dr. Howard McLeod of UNC-Chapel Hill to assess the risk of sensory neuropathy in breast cancer patients with genetic variations in drug metabolizing enzymes.

With the integration of Sequenom's MassArray, Gentris is able to design customizable, multiplex panels of genes for use in clinical trials.  The Company has already designed a custom panel for a top ten pharmaceutical company.  In addition, Gentris offers the iPLEX ADME PGx panel, which examines 192 of the most common variants in 36 ADME genes; the OncoCarta Panel v1.0, which is a comprehensive screen of 19 oncogenes and 238 mutations; and the Sequenom Sample ID Plus panel, which ensures that chain of custody is maintained and that there is amplifiable DNA in the sample.

The latest platform to be brought online is LifeTech's Ion Torrent Personal Genome Machine (PGM) for next generation sequencing. The Ion Torrent PGM allows for rapid, deep sequencing of large areas of the genome, which can efficiently identify both common and rare variations that may better predict the safety and efficacy of new drugs in development. Currently, Gentris is using the Ion Torrent PGM for discovery initiatives with its pharmaceutical partners as well as part of a collaboration with UNC-Chapel Hill. 

Related Links: www.gentris.com

Quotes:

"The expansion of our services by using these platform technologies allows us to provide our clients quality and regulated services in all phases of the clinical development pipeline," said Dr. L.Scott Clark, Gentris Chief Scientific Officer. "It's very exciting to use the Ion Torrent for discovery initiatives, because the depth of coverage and resolution can reveal new SNPs and variations that may be clinically relevant. However, these results need to be verified on a second platform which Gentris can perform because of its extensive experience with real-time PCR, Sanger sequencing, and Sequenom platforms."  

"The key to successfully implementing pharmacogenomics is to use the right platform to answer your specific question," said Dr. Howard McLeod, Director of the UNC Institute for Pharmacogenomics and Individualized Therapy and Gentris Chief Scientific Advisor. "By integrating multiple platforms, Gentris has the ability to address the needs of pharmaceutical clients during any stage in the clinical development of a drug. I'm excited to be working with them to discover, translate, and validate new biomarkers that will have an impact on patient care."

About Gentris Corporation:

Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.




'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
2. BioElectronics Corporation Announces Initiative for UK and German Markets
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Announces Agreement to Acquire GenturaDx
5. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
6. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
7. Celladon Corporation Receives Notice of Allowance from European Patent Office
8. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
9. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
10. Centene Corporation Selected for Ohio Medicaid Contract
11. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli Lilly ... William Sansum Diabetes Center have established a research collaboration ... diabetes through enhanced research, education and care. ... bears a disproportionate weight on Latino families in ... Kerr , M.D., FRCPE, director of Innovation and Research ...
(Date:3/23/2017)... Summary Global ... guide Primary Hyperoxaluria - Pipeline Review, H1 2017, ... Urinary System And Sex Hormones) pipeline landscape. ... recurrent kidney and bladder stones. It results from ... include blood in the urine, pain when urinating, ...
(Date:3/23/2017)... March 23, 2017  Digital Pharmacist Inc. ( ... a rapidly growing digital health company, announced today ... that allows patients to manage their prescriptions. Over ... as Denver Health Pharmacy, USave Pharmacy and Owen,s ... Digital Pharmacist accelerate its product development schedule, the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association ... The annual awards, now in their 12th year, are among the most prestigious in ... In 2016, the awards were retooled to recognize achievements in both large budget (over ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, ... treatments for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint ... the obstructive type, is increasingly being treated at dental offices with newly developed ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
Breaking Medicine News(10 mins):